Compare WRLD & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WRLD | OLMA |
|---|---|---|
| Founded | 1962 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 908.9M | 994.9M |
| IPO Year | 1994 | 2020 |
| Metric | WRLD | OLMA |
|---|---|---|
| Price | $191.33 | $11.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $44.89 |
| AVG Volume (30 Days) | 88.4K | ★ 1.9M |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 15.00 |
| EPS | ★ 6.88 | N/A |
| Revenue | ★ $585,166,700.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.51 | N/A |
| P/E Ratio | $27.84 | ★ N/A |
| Revenue Growth | ★ 3.60 | N/A |
| 52 Week Low | $110.00 | $4.47 |
| 52 Week High | $227.68 | $36.26 |
| Indicator | WRLD | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 48.22 | 45.34 |
| Support Level | $124.56 | $7.79 |
| Resistance Level | $227.68 | $13.09 |
| Average True Range (ATR) | 8.50 | 0.71 |
| MACD | -3.15 | -0.04 |
| Stochastic Oscillator | 3.53 | 26.50 |
World Acceptance Corp operates a small-loan consumer finance (installment loan) business. It offers short-term small installment loans, medium-term larger installment loans, related credit insurance and ancillary products and services to individuals. The Company generally serves individuals with limited access to other sources of consumer credit such as banks, credit unions, other consumer finance businesses and credit card lenders. The Company also offers income tax return preparation services to its loan customers and other individuals. The traditional installment loan industry is a fragmented segment of the consumer lending industry. The Company has one reportable segment: the consumer finance segment.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.